Many bioentrepreneurs incorrectly estimate the value of their technology by failing to account adequately for the cost, risk, ...

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management has a reasonably clear view of sales trends, margins, customer demand, and ...

For most of the past three decades, U.S.-listed biotech companies were fair proxies for homemade American science. But now, that assumption is fraying. By one estimate from investment bank Jefferies, ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

VHT offers significantly lower ownership costs, with a 0.09% expense ratio compared to XBI's 0.35%. XBI provides targeted focus on biotechnology, while VHT offers exposure to the entire healthcare ...

The internet is side-eyeing Vaccinex Inc – but is this tiny biotech actually worth your money? You keep seeing tickers like VCNX pop up in your feed, everyone yelling about "next big biotech" and ...